Coya Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | — | — | — |
| SG&A Expense | $11.4M | $8.9M | $7.8M | $4.8M |
| Operating Income | $-22.6M | $-17.2M | $-7.9M | $-9.8M |
| Operating Margin | -283.9% | -485.4% | -131.7% | — |
| Interest Expense | — | — | — | — |
| Pretax Income | $-21.2M | $-15.6M | $-7.3M | $-12.2M |
| Income Tax Expense | $3.1K | $-720.3K | $723.9K | $0 |
| Net Income | $-21.2M | $-14.9M | $-8.0M | $-12.2M |
| Net Margin | -267.1% | -418.7% | -133.1% | — |
| EPS (Basic) | $-1.27 | $-0.98 | $-0.79 | $-1.18 |
| EPS (Diluted) | $-1.27 | $-0.98 | $-0.79 | $-1.18 |
| Shares Outstanding (Basic) | 16.7M | 15.2M | 10.2M | 10.4M |
| Shares Outstanding (Diluted) | 16.7M | 15.2M | 10.2M | 10.4M |
| Dividends Per Share | — | — | — | — |